Physician profile
Anna Ward
NPI 1962799676
$1,053.81
in general payments reported to CMS, 2019-2025
20 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $79.70 · 2023: $40.92 · 2024: $496 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145.77 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $137.98 | 2024 | Spravato |
| Averitas Pharma INC. | $129.60 | 2024-2025 | Qutenza |
| Grifols USA, LLC | $90.99 | 2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $78.54 | 2024 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $74.26 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $71.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $59.84 | 2021-2025 | |
| Pfizer INC. | $48.89 | 2025 | |
| Lilly USA, LLC | $40.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $38.29 | 2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $25.57 | 2025 | Rybelsus, Ozempic |
| Ironshore Pharmaceuticals INC. | $16.86 | 2023 | Jornay Pm |
| Amgen INC. | $16.85 | 2024 | Evenity, Prolia |
| Seqirus USA INC | $16.56 | 2025 | Fluad, Flucelvax |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.89 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $13.25 | 2021 | |
| Esperion Therapeutics, INC. | $12.54 | 2021 | |
| Amarin Pharma, INC. | $12.08 | 2022 | |
| Medela LLC | $9.17 | 2023 | Invia Motion Endure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.